Compare CTMX & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTMX | FPF |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 977.1M | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | CTMX | FPF |
|---|---|---|
| Price | $4.04 | $18.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.10 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 96.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $76,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $17.21 |
| 52 Week High | $8.21 | $19.75 |
| Indicator | CTMX | FPF |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 50.01 |
| Support Level | $4.02 | $17.21 |
| Resistance Level | $4.72 | $18.71 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 3.70 | 42.09 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.